Newsroom | 51891 results
Sorted by: Latest
-
City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options at the AACR Annual Meeting, which st...
-
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o...
-
Longhorn Vaccines and Diagnostics Presents Compelling Data on LHNVD-303 Vaccine for Sepsis Related to Bacterial Infections at the World Vaccine Congress
BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening com...
-
Samenvatting: Incyte licht oncologiegegevens uit vroeg stadium toe tijdens de Annual Meeting 2025 van de American Association for Cancer Research
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) kondigde vandaag aan dat het bedrijf nieuwe gegevens uit het vroege stadium uit haar oncologieportfolio zal voorstellen tijdens de Annual Meeting 2025 van de AACR (American Association of Cancer Research) in Chicago, IL, die doorgaat van 25 tot 30 april. “Tijdens AACR zullen we gegevens voorstellen uit programma's van het vroege stadium binnen onze oncologieportfolio, onder andere voor patiënten met myeloproliferatieve neoplasmata, eiersto...
-
Incyte présentera de nouvelles données sur ses traitements oncologiques en phase précoce lors du congrès annuel 2025 de l’American Association for Cancer Research
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq : INCY) a annoncé aujourd’hui qu’elle présentera de nouvelles données préliminaires issues de son portefeuille de traitements oncologiques lors du congrès annuel 2025 de l’American Association for Cancer Research (AACR), qui se tiendra à Chicago (Illinois) du 25 au 30 avril. « À l’occasion du congrès de l'AACR, nous dévoilerons des données préliminaires issues de nos programmes cliniques en phase initiale, portant notamment sur les néoplasme...
-
Incyte präsentiert Daten aus frühen Phasen der Onkologieforschung auf der Jahrestagung 2025 der American Association for Cancer Research
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass das Unternehmen auf der Jahrestagung 2025 der American Association for Cancer Research (AACR) vom 25. bis 30. April in Chicago, Illinois, neue Daten aus frühen Phasen seines Onkologieportfolios vorstellen wird. „Auf der AACR werden wir Daten aus frühen Programmen unseres Onkologie-Portfolios vorstellen, darunter für Patienten mit myeloproliferativen Neoplasien, Eierstockkrebs und anderen soliden Tumoren“, sagte...
-
Riassunto: Incyte evidenzierà i primi dati oncologici al Convegno annuale 2025 dell'American Association for Cancer Research
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025...
-
Resumen: Incyte presentará datos oncológicos de etapa inicial en la reunión anual de la American Association for Cancer Research 2025
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025...
-
Southern California Cities Honor Reproductive Partners Medical Group During National Infertility Awareness Week
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Reproductive Partners Medical Group (RPMG), a leading fertility clinic in Southern California and proud member of the Ivy Fertility network, has been honored with two city proclamations, from Beverly Hills and Westminster, recognizing National Infertility Awareness Week (NIAW). This recognition shines a spotlight on the impact of infertility and the need for increased awareness, support, and equitable access to fertility care. National Infertility Awarene...
-
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design update on the ongoing multicenter study Agni-01 (NCT06060613), Obsidian will share preclinical data from our cytoDRiVE® platform demonstrating spatiotemp...
